GLPwatch
Papers (12034)
Page 178 of 201, ranked by citation count.
- [in process].
- Clinical Data Mega-Collection of Obesity and Obesity-Related Trials: Primary Inclusion Criteria from All Studies and Highlights of Clinical Efficacy Analysis of GLP-1 Drugs.
- Body Composition and Lifestyle Interventions in Pharmacological Treatment of Acquired Hypothalamic Obesity: A Systematic Review of Randomized Controlled Trials.
- Efficacy and safety of GLP-1 receptor agonists for adolescents and children with obesity: a meta-analysis of randomized controlled trials.
- [Oral semaglutide, first oral GLP-1 receptor agonist (Rybelsus®)].
- Weight reduction and treatment adherence with tirzepatide using the Individualized Virtual Integrative Medicine (IVIM) protocol.
- Beyond weight loss: multisystem benefits of obesity medications.
- [Cloning, expressing of exendin-4 analogue and bioactivity analysis in vivo].
- Effects of liraglutide on abdominal fat distribution and glucose metabolism in Chinese subjects with obesity.
- Mazdutide and Orforglipron-New Evidence in Obesity and Diabetes.
- In type 2 diabetes, glargine and liraglutide each improved glycemic outcomes at 5 y vs. glimepiride or sitagliptin.
- Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis.
- MASH and liver fibrosis: Clinical trials to watch.
- Potential of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Mitigating Metabolic Side Effects Associated With Clozapine or Olanzapine Therapy: A Literature Review.
- Repurposed Drugs and Cardiovascular Morbidity: A Cost-Effectiveness Analysis.
- Semaglutide-Induced Weight Loss Is the Main Determinant for the Improvement of Hepatic Biochemistry and Elastographic Repeated Measurements with FibroScan® in Patients with Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease.
- Incretin analogues as cardiovascular agents: a state-of-the-art review.
- Mechanistically resolved prediction of compound hepatotoxicity using primary human liver spheroids-Application to recent real-world cases.
- Does evidence matter? Comparative effectiveness research and prescribing of Type 2 diabetes mellitus drugs.
- Association of Tirzepatide Use With Clinical Outcomes After TAVR in Obese Patients: A Propensity Score-Matched Real-World Study.
- Nutritional intake changes during GLP-1 receptor agonist therapy: A systematic review and meta-analysis.
- Liraglutide Is Probably the Best Second Drug to Prevent Cardiovascular Events in Patients With Type 2 Diabetes Mellitus Who Take Metformin.
- Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the SURMOUNT-1 Trial.
- Beyond weight loss: tirzepatide as a dual GIP/GLP-1 receptor agonist for obstructive sleep apnea.
- GLP-1 receptor agonists in pediatric obesity.
- Comparative Effectiveness of Glucagon-like Peptide-1 Receptor Agonists Versus Oral Agents for Insulin Discontinuation in Type 2 Diabetes : A Target Trial Emulation.
- Evaluation of the Clinical Effectiveness and Cost-Effectiveness of Tirzepatide for Type 2 Diabetes in Canada Using Bayesian Transportability Analysis.
- Renoprotective effect of liraglutide on diabetic nephropathy by modulation of Krüppel-like transcription factor 5 expression in rats.
- Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials.
- [Twice-daily and weekly exenatide: clinical profile of two pioneer formulations in incretin therapy].
- GLP-1/GIP dual agonist tirzepatide in obstructive sleep apnea syndrome: mechanisms, evidence, and clinical perspectives.
- Efficacy of semaglutide in IgA nephropathy with obesity: a case report.
- Tirzepatide: A promising treatment for obesity?
- Healthcare Resource Utilization and Costs in Individuals Who Discontinue Liraglutide and Who Switch from Liraglutide to Once-Weekly Injectable Semaglutide.
- Gut-Derived FGF15 Modulates Lean Mass, Bone, and Bile Acid Responses to Weight Loss.
- Peripheral nerve complications from medications utilised for weight loss: a systematic review.
- Exploratory Analysis of Liraglutide Effects on Obstructive Sleep Apnea and Health-Related Quality of Life in Individuals With Obesity and COPD: A Secondary Analysis of a Randomised Controlled Trial.
- Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics in participants with T2D: subgroup analysis of SURPASS-SWITCH.
- Implications of Glucagon-Like Peptide-1 Receptor Agonists in Otolaryngology - Head and Neck Surgery: A Review.
- GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists in Children and Adolescents with Obesity: Clinical Outcomes and the Impact of Nutritional and Behavioral Co-Interventions-A Systematic Review.
- Choice of first injectable therapy in type 2 diabetes.
- GLP-1 Receptor Agonists or Dual GLP-1/GIP Receptor Agonists vs. SGLT2 Inhibitors in Patients with Atrial Fibrillation and HFpEF: A Propensity-Matched Real-World Analysis.
- Glucagonlike Peptide-1 (GLP-1) Receptor Agonists for Cardiometabolic Risk in Severe Mental Illness: A Narrative Review.
- Reestimation of Medicare Spending for Semaglutide After Most Favored Nation and Medicare Drug Price Negotiation Announcements.
- Microfluidic-assisted formulation of hydrophobic ion pairing-based solid lipid nanoparticles for semaglutide delivery.
- Lixisenatide clinical experience on patients with type 2 diabetes and obesity in endocrinology offices in Malaga.
- Immediate Impact of Switching from Dipeptidyl Peptidase 4 (DPP4) Inhibitors to Low-Dose (0.3 mg) Liraglutide on Glucose Profiles: A Retrospective Observational Study.
- IgG Fc-Binding Motif-Conjugated Exendin-4: A Long-Acting Hypoglycemic Agent via Broad-Spectrum Antibody Engagement for Type 2 Diabetes Therapy.
- Dual incretin analogue tirzepitide - SURMOUNTing the challenge of obesity induced obstructive sleep apnea.
- Safety Signals of GLP-1 Receptor Agonists: A Multi-Method Pharmacovigilance Analysis of FAERS (2018-2025) With Sensitivity-Stratified Prioritisation, Notoriety-Bias Assessment, and Cross-Database Validation.
- Development and Validation of a Liquid Chromatography/Tandem Mass Spectrometry Method for the Quantification of the GLP-1 Analog Semaglutide in Rat Plasma, and Its Application in a Pharmacokinetic Study.
- Chronic semaglutide treatment reveals stage-dependent changes to feeding behavior and metabolic adaptations in male mice.
- Post-cessation Weight Regain After Weight Management Medications: A Systematic Review and Meta-Analysis.
- Semaglutide-Induced Hepatic Injury: A Rare Case of Drug Induced Liver Injury.
- Incretin-based therapies, alcohol and tobacco use, and acute substance-related events: emerging implications for cardiovascular medicine.
- Burden and Risk of Depression in Patients Receiving Semaglutide: A Systematic Review and Meta-Analysis.
- New Indication for Weight Loss Drug Semaglutide.
- Acute Kidney Injury from Mononuclear Cell-Predominated Interstitial Nephritis After Introduction of a Glucagon-Like Peptide-1 Receptor Agonist: A Case Report.
- Gastrointestinal adverse events associated with tirzepatide: A bibliometric and pharmacovigilance analysis.
- Differential Biliary Adverse Event Signals Among Glp-1 Receptor Agonists: A FAERS Disproportionality Analysis.